# Gujarat Themis Biosyn shares jumped over 15% on Friday, 24 April as the company prepares to acquire a range of anti-tuberculosis (TB) and anti-infective brands from Sanofi.

*biotech · news · 2026-04-24 · Livemint*

## Key points

- Gujarat Themis Biosyn will acquire 13 anti-TB and anti-infective brands from Sanofi for €158 million.
- The acquisition covers commercial rights but excludes manufacturing facilities and personnel, ensuring asset-light expansion.
- The acquired portfolio reported net sales of €62 million for fiscal year ending 2025.
- This transaction is nearly 50% of Gujarat Themis Biosyn's current market capitalization.

**Companies:** Gujarat Themis Biosyn
**Countries:** France, India

[Read the full story on Livemint](https://www.livemint.com/market/stock-market-news/gujaratbased-pharma-stock-jumps-over-15-despite-stock-market-crash-heres-why-11777014055217.html)

---

Canonical: https://newsio.io/n/32004164-1ea1-48da-b026-fc6a804f1fe1/gujarat-themis-biosyn-shares-jumped-over-15-on-friday-24-april-as-the-company-pr
Summarized by Newsio from Livemint. https://newsio.io/how-it-works